Get the Stockscreener App
1.1184
2.63%
-0.0316
Novabay Pharmaceuticals Inc stock is traded at $1.1184, with a volume of 93,303.
It is down -2.63% in the last 24 hours and down -17.66% over the past month.
NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets non-antibiotic and anti-infective products for the eye care market in the United States, China, and internationally. It offers Avenova, a prescription product for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye; NeutroPhase for wound care market; CelleRx for the aesthetic dermatology market; Aganocide compounds patented synthetic molecules for use against bacteria, viruses, and fungi; auriclosene irrigation solution for urology; and intelli-Case, a device for soft and rigid gas permeable contact lenses. NovaBay Pharmaceuticals, Inc. has collaboration and license agreement with Virbac to develop auriclosene, a proprietary compound for veterinary markets. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is based in Emeryville, California.
See More
Previous Close:
$1.15
Open:
$1.13
24h Volume:
93,303
Relative Volume:
0.01
Market Cap:
$6.49M
Revenue:
$4.75M
Net Income/Loss:
$-7.83M
P/E Ratio:
5.1373
EPS:
0.2177
Net Cash Flow:
$-7.24M
1W Performance:
-9.69%
1M Performance:
-17.66%
6M Performance:
+90.90%
1Y Performance:
+49.31%
1-Day Range:
$1.09
$1.14
1-Week Range:
$1.09
$1.3097
52-Week Range:
$0.46
$4.44
Novabay Pharmaceuticals Inc Stock (NBY) Company Profile
Name
Novabay Pharmaceuticals Inc
Sector
Industry
Phone
510-899-8800
Address
2000 Powell Street, Suite 1150, Emeryville, CA
Compare NBY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NBY
Novabay Pharmaceuticals Inc
|
1.115 | 6.91M | 4.75M | -7.83M | -7.24M | 0.2177 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.63 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.39 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.26 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
821.78 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
183.80 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Novabay Pharmaceuticals Inc Stock (NBY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-18-19 | Initiated | Ladenburg Thalmann | Buy |
| Jul-06-18 | Reiterated | H.C. Wainwright | Buy |
| Nov-15-17 | Reiterated | Laidlaw | Buy |
| Jun-05-17 | Initiated | ROTH Capital | Buy |
| Mar-27-17 | Initiated | Laidlaw | Buy |
| Feb-06-17 | Initiated | Rodman & Renshaw | Buy |
| Mar-07-16 | Downgrade | Maxim Group | Buy → Hold |
| Dec-14-15 | Reiterated | Maxim Group | Buy |
| Apr-30-15 | Resumed | Maxim Group | Buy |
| Mar-06-13 | Initiated | Ascendiant Capital Markets | Strong Buy |
| Jan-03-08 | Initiated | Dawson James | Speculative Buy |
View All
Novabay Pharmaceuticals Inc Stock (NBY) Latest News
Will NovaBay Pharmaceuticals Inc. (B9P0) stock announce a stock splitJuly 2025 Technicals & Safe Capital Growth Plans - newser.com
Why NovaBay Pharmaceuticals Inc. stock fits value portfoliosRate Cut & Safe Capital Growth Stock Tips - newser.com
How NovaBay Pharmaceuticals Inc. stock performs in interest rate cycles2025 Major Catalysts & Fast Exit and Entry Strategy Plans - newser.com
Price momentum metrics for NovaBay Pharmaceuticals Inc. explained2025 Volatility Report & Intraday High Probability Alerts - newser.com
Why analysts recommend NovaBay Pharmaceuticals Inc. (B9P0) stockJuly 2025 Breakouts & Real-Time Volume Analysis - newser.com
How NovaBay Pharmaceuticals Inc. stock moves on employment dataIPO Watch & Free Growth Oriented Trading Recommendations - newser.com
Will NovaBay Pharmaceuticals Inc. (B9P0) stock outperform Dow JonesLong Setup & Fast Entry and Exit Trade Plans - newser.com
Why NovaBay Pharmaceuticals Inc. stock is trending among retail traders2025 Earnings Impact & Daily Market Momentum Tracking - newser.com
Heatmap analysis for NovaBay Pharmaceuticals Inc. and competitorsWeekly Profit Analysis & Community Verified Watchlist Alerts - newser.com
Is NovaBay Pharmaceuticals Inc. stock undervalued vs historical averagesWeekly Trade Review & Step-by-Step Trade Execution Guides - newser.com
Is NovaBay Pharmaceuticals Inc. (B9P0) stock positioned for digital growth eraStop Loss & Technical Pattern Based Signals - newser.com
What margin trends mean for NovaBay Pharmaceuticals Inc. stockWeekly Trend Summary & Target Return Focused Picks - newser.com
Will breakout in NovaBay Pharmaceuticals Inc. lead to full recoveryQuarterly Performance Summary & Community Verified Watchlist Alerts - newser.com
Is NovaBay Pharmaceuticals Inc. stock undervalued after correctionProduct Launch & Free Reliable Trade Execution Plans - newser.com
How analysts revise price targets for NovaBay Pharmaceuticals Inc. (B9P0) stock2025 EndofYear Setup & Free Fast Gain Swing Trade Alerts - newser.com
Is NovaBay Pharmaceuticals Inc. stock undervalued historicallyWeekly Volume Report & Weekly Market Pulse Updates - newser.com
Statistical indicators supporting NovaBay Pharmaceuticals Inc.’s strengthPortfolio Return Summary & Safe Capital Growth Stock Tips - newser.com
What technical signals suggest for NovaBay Pharmaceuticals Inc. stockJuly 2025 Breakouts & High Yield Equity Trading Tips - newser.com
Will NovaBay Pharmaceuticals Inc. (B9P0) stock benefit from commodity supercycle2025 Analyst Calls & Low Risk High Reward Ideas - newser.com
Is NovaBay Pharmaceuticals Inc. (B9P0) stock a top dividend aristocrat candidateMarket Movement Recap & Community Driven Trade Alerts - newser.com
Can NovaBay Pharmaceuticals Inc. stock withstand economic slowdownQuarterly Portfolio Summary & AI Enhanced Execution Alerts - newser.com
Is NovaBay Pharmaceuticals Inc. stock attractive for retirement portfolios2025 Institutional Moves & Daily Stock Momentum Reports - newser.com
Published on: 2025-10-31 05:01:56 - newser.com
Published on: 2025-10-31 04:04:18 - newser.com
NovaBay Pharmaceuticals Inc. stock trendline breakdownJuly 2025 Analyst Calls & Safe Capital Allocation Plans - newser.com
Published on: 2025-10-31 00:58:47 - newser.com
Can NovaBay Pharmaceuticals Inc. stock beat analyst consensus2025 Analyst Calls & AI Enhanced Trade Execution Alerts - newser.com
What analysts say about NovaBay Pharmaceuticals Inc stockAnalyst Downgrades & Access Free Risk Analysis Before You Invest - earlytimes.in
Novabay Pharmaceuticals Inc Stock (NBY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.29%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):